Ventricular Tachycardia in Hypertrophic Cardiomyopathy
Definition
Ventricular tachycardia in hypertrophic cardiomyopathy (HCM) is not a single entity. In young patients with myocyte disarray and increased left ventricular mass, the dominant arrhythmia is polymorphic ventricular tachycardia or ventricular fibrillation; sustained monomorphic ventricular tachycardia is less common and usually reflects scar-related re-entry in older patients, dilated-phase HCM, or an apical aneurysm. The distinction matters clinically because monomorphic ventricular tachycardia is mappable and ablatable, whereas polymorphic ventricular tachycardia and ventricular fibrillation are treated with defibrillation and substrate-independent strategies. (sources/hcm-vt-ablation-jacep-2025, rating: high)
Key Concepts
Mechanisms and substrate distribution
- Most HCM-related monomorphic ventricular tachycardias are three-dimensional re-entrant circuits with mid-myocardial involvement. In the largest reported ablation cohort (32 patients, 28 mapped ventricular tachycardias), 25 were scar-mediated re-entries, 2 were focal, and 1 was bundle branch re-entry. (sources/hcm-vt-ablation-jacep-2025, rating: high)
- The distribution is regionally biased: left ventricular lateral wall 15 patients (46.9%), apical aneurysm 6 (18.8%), superior basal region 6 (18.8%), left posterior papillary muscle 3 (9.4%), interventricular septum 1 (3.1%), and His-Purkinje system 1 (3.1%). (sources/hcm-vt-ablation-jacep-2025, rating: high)
- The depth of the circuit varies by region. Incomplete endocardial re-entry accounted for 17.9% of circuits, incomplete epicardial re-entry for 28.6%, transmural re-entry for 14.3%, and exclusive mid-myocardial re-entry for 28.6%. The lateral wall was predominantly incomplete epicardial (77.8%), the apical aneurysm predominantly transmural (66.7%), and the superior basal region predominantly exclusive mid-myocardial (87.5%). (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Septal hypertrophy and fibrosis are common, but septal ventricular tachycardia is rare. Only one of 32 patients had a septal circuit, and it was exclusively mid-myocardial; the reason for the dissociation between septal substrate and septal arrhythmia is unknown. (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Late gadolinium enhancement is intramural or subepicardial, corresponding to the low-voltage areas and critical isthmus in most patients; cardiac magnetic resonance was available in only 9 of 32 patients, so the imaging–electrophysiology correlation remains incomplete. (sources/hcm-vt-ablation-jacep-2025, rating: high)
Apical aneurysm phenotype
- Apical aneurysm ventricular tachycardia has a characteristic electrocardiogram: northwest axis in 80% and QS complexes across the lateral precordial leads in 100%, with right bundle branch block morphology in 67% and left bundle branch block in 33%. (sources/apical-hcm-vt-ablation-jacep-2018, rating: medium)
- The substrate is endocardial in most patients. Endocardial voltage mapping showed a low-voltage area and late potentials within the aneurysm in 80% of patients; endocardial ablation rendered the clinical ventricular tachycardia non-inducible in all 15 patients (100% acute success), with recurrence in 13.3% at 12 months in the original series. (sources/apical-hcm-vt-ablation-jacep-2018, rating: medium)
- The apical-aneurysm subgroup does better than dilated-phase HCM. In the meta-analysis, acute success was 96.45% versus 85% (P for interaction = 0.02), and freedom from recurrent ventricular tachycardia after the last ablation was 96.45% versus 79.7% (P = 0.03). (sources/hcm-vt-ablation-meta-jce-2023, rating: medium)
- Transmural circuits are common in the aneurysm. In the Jin cohort, 66.7% of apical-aneurysm circuits were transmural, and 4 of 6 patients underwent combined endocardial and epicardial ablation; the long-term success rate after the index procedure was 83.3%. (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Apical aneurysm is a high-risk phenotype. Five of 23 patients with HCM and electrical storm had an apical aneurysm (21.7%), and the paper cites a five-fold increase in arrhythmic events with aneurysm. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
Catheter ablation outcomes
| Cohort | Patients | Acute success | Freedom from VT after index | After last ablation | Follow-up |
|---|---|---|---|---|---|
| Meta-analysis (Garg 2023) | 68 | 84.5% | 70.2% | 82.8% | 18.3 ± 11.7 months |
| Single-centre (Jin 2025) | 32 | 87.5% | 62.5% | 71.9% | median 31 months |
| Apical aneurysm (Igarashi 2018) | 15 | 100% | 86.7% at 12 months | — | 12 months |
- Outcome depends on the site of origin. In the Jin cohort, long-term success after the index procedure was 73.3% for lateral wall, 83.3% for apical aneurysm, 100% for papillary muscle, 100% for His-Purkinje, 0% for superior basal region and 0% for the single septal circuit. (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Repeat procedures are common. In the meta-analysis, 27.9% required multiple ablations; in the Jin cohort, 5 patients underwent repeat ablation, mostly at the same site, and the overall success after multiple procedures was 71.9%. (sources/hcm-vt-ablation-meta-jce-2023, rating: medium) (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Complications are not negligible. The pooled complication rate was 9.1%, including pericardial effusion requiring drainage, complete atrioventricular block, left anterior descending artery occlusion, phrenic nerve palsy and groin haematoma; mortality was 0.8%. (sources/hcm-vt-ablation-meta-jce-2023, rating: medium)
- An implantable cardioverter-defibrillator remains necessary after ablation. One patient in the apical-aneurysm series who refused an ICD died suddenly 17 days after an apparently successful ablation. (sources/apical-hcm-vt-ablation-jacep-2018, rating: medium)
Electrical storm in HCM
- Monomorphic ventricular tachycardia dominates. In the first dedicated multicentre cohort, 78.3% of patients had monomorphic ventricular tachycardia and 30.4% had ventricular fibrillation. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
- Antiarrhythmic drugs often suffice. Amiodarone was used in 87%, beta-blockers in 70%, lidocaine in 39.1% and magnesium in 34.8%; only 13% required deep sedation, 8.6% extracorporeal membrane oxygenation and 4.3% stellate ganglion block. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
- Ablation did not improve outcomes in this cohort. Ten patients (43.5%) underwent ablation; recurrence occurred in 2 of the ablated group versus 6 of the non-ablated group (risk ratio 0.67; 95% CI 0.37–1.22; P = 0.380), and ablation was not associated with freedom from recurrence (HR 2.52; 95% CI 0.56–11.4; P = 0.231) or survival (P = 0.125). (sources/hcm-electrical-storm-jacep-2025, rating: medium)
- Mortality is high. In-hospital mortality was 9%, one-year survival was 82.7%, and 26% of patients died over a median follow-up of 18 months. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
Native HCM-VT versus lead-related VT
The HCM-VT literature maps native scar-related circuits in the lateral wall, apical aneurysm, superior basal region, septum and papillary muscle. A lead inserted into HCM myocardium is a different potential substrate: local trauma, fibrosis and mechanical irritation at the insertion site can create or mark a slow-conduction zone. The HCM-VT ablation cohorts do not address lead insertion sites, and the lead-related proarrhythmia literature is separate. A ventricular tachycardia that maps to a lead insertion site rather than to a recognised HCM substrate should therefore be interpreted as lead-associated until proven otherwise; this is the question raised by the present case.
Contradictions / Open Questions
- Ablation in HCM electrical storm: benefit unproven. The only dedicated HCM electrical-storm cohort found no association between ablation and recurrence or survival, whereas HCM-VT ablation cohorts report high acute success and durable freedom in non-storm patients. The difference may reflect storm severity, substrate, epicardial access, single versus multiple procedures, and selection bias. (sources/hcm-electrical-storm-jacep-2025, rating: medium) (sources/hcm-vt-ablation-meta-jce-2023, rating: medium) (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Apical aneurysm VT: endocardial alone or combined endo-epicardial? The Igarashi series achieved 100% acute success and 13.3% recurrence with endocardial ablation alone, whereas the Jin cohort found transmural re-entry in 66.7% of apical-aneurysm circuits and used combined endocardial-epicardial ablation in most. The optimal strategy is unresolved. (sources/apical-hcm-vt-ablation-jacep-2018, rating: medium) (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Septal VT is rare but has the worst outcome. The septum is the most common site of hypertrophy and fibrosis, yet only one of 32 patients had a septal circuit, and that patient had 0% long-term success after the index procedure. Whether this reflects a true biological resistance or a mapping/ablation limitation is unknown. (sources/hcm-vt-ablation-jacep-2025, rating: high)
- Who should undergo ablation versus antiarrhythmic drugs? No randomised trial exists. The electrical-storm cohort's ablation group had lower ejection fraction and more prior ventricular arrhythmia, suggesting selection by disease severity rather than a random comparison. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
- Apical aneurysm as an ICD indication remains guideline-concordant only in the United States. AHA 2024 treats apical aneurysm with transmural scar as a major sudden-death risk factor (Class IIa), whereas ESC 2023 declines to accept it as a sole indication; these papers reinforce the high-risk phenotype but do not resolve the disagreement. (sources/hcm-electrical-storm-jacep-2025, rating: medium)
- How often does a lead insertion site create a VT substrate in HCM? The HCM-VT mapping literature does not address lead insertion sites, and the lead-related proarrhythmia literature is separate. The incidence, mechanism and optimal management of lead-associated VT in HCM are unknown.
- Long-term durability after ablation is uncertain. Freedom from recurrence is 70–83% in observational cohorts, repeat procedures are common, and there is no randomised comparison with antiarrhythmic drugs or with a uniform ablation strategy. (sources/hcm-vt-ablation-meta-jce-2023, rating: medium) (sources/hcm-vt-ablation-jacep-2025, rating: high)
Connections
- entities/HCM — the parent cardiomyopathy
- concepts/HCM-Management — management of HCM, including ventricular arrhythmia
- concepts/HCM-Risk-SCD — sudden-death risk and ICD selection
- concepts/Electrical-Storm — the electrical-storm syndrome and acute management
- concepts/VT-Ablation — the general ablation framework
- concepts/VT-Ablation-Nonischemic-Cardiomyopathy — the non-ischaemic substrate
- concepts/Epicardial-VT-Ablation — the epicardial approach
- concepts/Late-Gadolinium-Enhancement — scar imaging
- entities/ICD — device therapy